Kisun Pharmaceutical Co., Ltd.

Overview

Kisun Pharmaceutical Co., Ltd. is a leading pharmaceutical company in China, specializing in the development and distribution of innovative medicine and health solutions. The company is dedicated to improving patient outcomes through research and development of advanced therapeutic products.

Therapeutic areas

API / Drug Master Files

Kisun Pharmaceutical Co., Ltd. holds 16 active (37 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• MOMELOTINIB INTERMEDIATE DActive2026-03-03
• NILOTINIB HYDROCLORIDE MONOHYDRATEActive2025-04-30
• NEOSTIGMINE METHYLSULFATEActive2023-02-24
• DESVENLAFAXINE SUCCINATEActive2022-07-04
• LENALIDOMIDEActive2021-04-26
• DASATINIB ANHYDROUSActive2020-05-31
• TEMOZOLOMIDEActive2013-10-22
• DASATINIBActive2010-04-21
• IRINOTECAN HYDROCHLORIDEActive2010-01-10
• DOCETAXEL ANHYDROUSActive2009-02-26
• GRANISETRON BASEActive2008-09-29
• GRANISETRON HYDROCHLORIDE (NON-STERILE)Active2006-04-10
• FLUMAZENILActive2004-12-12
• GATIFLOXACIN DRUG SUBSTANCEActive2001-08-27
• ERYTHROMYCIN BASE USP 23Active1999-12-15

Showing 15 of 37 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Kisun Pharmaceutical Co., Ltd. in our records. PharmaTek screens the full directory against live FDA enforcement data.